BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Parisinos CA, Wilman HR, Thomas EL, Kelly M, Nicholls RC, McGonigle J, Neubauer S, Hingorani AD, Patel RS, Hemingway H, Bell JD, Banerjee R, Yaghootkar H. Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis. J Hepatol 2020;73:241-51. [PMID: 32247823 DOI: 10.1016/j.jhep.2020.03.032] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 14.7] [Reference Citation Analysis]
Number Citing Articles
1 Garfield V, Salzmann A, Burgess S, Chaturvedi N. A Guide for Selection of Genetic Instruments in Mendelian Randomization Studies of Type 2 Diabetes and HbA1c: Toward an Integrated Approach. Diabetes 2023;72:175-83. [PMID: 36669000 DOI: 10.2337/db22-0110] [Reference Citation Analysis]
2 Михайлова СВ, Иванощук ДЕ, Орлов ПС, Денисова ДВ, Шахтшнейдер ЕВ. Анализ ассоциации распространенного варианта rs13107325 гена-транспортера двухвалентных катионов SLC39A8 с показателями липидного обмена подростков г. Новосибирска. Атеросклероз 2023;18:354-361. [DOI: 10.52727/2078-256x-2022-18-4-354-361] [Reference Citation Analysis]
3 McCracken C, Raisi-Estabragh Z, Veldsman M, Raman B, Dennis A, Husain M, Nichols TE, Petersen SE, Neubauer S. Multi-organ imaging demonstrates the heart-brain-liver axis in UK Biobank participants. Nat Commun 2022;13:7839. [PMID: 36543768 DOI: 10.1038/s41467-022-35321-2] [Reference Citation Analysis]
4 Wang F, Mi J, Bai X, Ruan G, Zhang Y, Yu K. Interleukins and the risk of non-alcoholic fatty liver disease: a two-sample Mendelian randomization study.. [DOI: 10.21203/rs.3.rs-1751879/v2] [Reference Citation Analysis]
5 Kalinowski P, Smyk W, Nowosad M, Paluszkiewicz R, Michałowski Ł, Ziarkiewicz-Wróblewska B, Weber SN, Milkiewicz P, Lammert F, Zieniewicz K, Krawczyk M. MTARC1 and HSD17B13 Variants Have Protective Effects on Non-Alcoholic Fatty Liver Disease in Patients Undergoing Bariatric Surgery. Int J Mol Sci 2022;23. [PMID: 36555467 DOI: 10.3390/ijms232415825] [Reference Citation Analysis]
6 Park J, MacLean MT, Lucas AM, Torigian DA, Schneider CV, Cherlin T, Xiao B, Miller JE, Bradford Y, Judy RL, Verma A, Damrauer SM, Ritchie MD, Witschey WR, Rader DJ; Regeneron Genetics Center. Exome-wide association analysis of CT imaging-derived hepatic fat in a medical biobank. Cell Rep Med 2022;3:100855. [PMID: 36513072 DOI: 10.1016/j.xcrm.2022.100855] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Au Yeung SL, Borges MC, Wong THT, Lawlor DA, Schooling CM. Evaluating the role of non-alcoholic fatty liver disease in cardiovascular diseases and type 2 diabetes: a Mendelian randomization study in Europeans and East Asians. International Journal of Epidemiology 2022. [DOI: 10.1093/ije/dyac212] [Reference Citation Analysis]
8 Li S, Ma C, Li Y, Chen R, Liu Y, Wan LP, Xiong Q, Wang C, Huo Y, Dang X, Yang Y, Lv L, Chen X, Sheng N, Li W, Luo XJ. The schizophrenia-associated missense variant rs13107325 regulates dendritic spine density. Transl Psychiatry 2022;12:361. [PMID: 36056013 DOI: 10.1038/s41398-022-02137-z] [Reference Citation Analysis]
9 Thanaj M, Basty N, Cule M, Sorokin EP, Whitcher B, Bell JD, Thomas EL. Liver Shape is Associated with Disease and Anthropometric Traits.. [DOI: 10.1101/2022.08.18.22278951] [Reference Citation Analysis]
10 Baratta F, D'erasmo L, Bini S, Pastori D, Angelico F, Del Ben M, Arca M, Di Costanzo A. Heterogeneity of non-alcoholic fatty liver disease (NAFLD): Implication for cardiovascular risk stratification. Atherosclerosis 2022. [DOI: 10.1016/j.atherosclerosis.2022.08.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Dearlove DJ, Hodson L. Intrahepatic triglyceride content: influence of metabolic and genetics drivers. Curr Opin Clin Nutr Metab Care 2022;25:241-7. [PMID: 35762159 DOI: 10.1097/MCO.0000000000000838] [Reference Citation Analysis]
12 Civelek M, Podszun MC. Genetic Factors Associated with Response to Vitamin E Treatment in NAFLD. Antioxidants 2022;11:1284. [DOI: 10.3390/antiox11071284] [Reference Citation Analysis]
13 Samuelson DR, Haq S, Knoell DL. Divalent Metal Uptake and the Role of ZIP8 in Host Defense Against Pathogens. Front Cell Dev Biol 2022;10:924820. [PMID: 35832795 DOI: 10.3389/fcell.2022.924820] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Verouti SN, Pujol-giménez J, Bermudez-lekerika P, Scherler L, Bhardwaj R, Thomas A, Lenglet S, Siegrist M, Hofstetter W, Fuster DG, Hediger MA, Escher G, Vogt B. The Allelic Variant A391T of Metal Ion Transporter ZIP8 (SLC39A8) Leads to Hypotension and Enhanced Insulin Resistance. Front Physiol 2022;13:912277. [DOI: 10.3389/fphys.2022.912277] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Spiers J, Brindley JH, Li W, Alazawi W. What's new in non-alcoholic fatty liver disease? Frontline Gastroenterol 2022;13:e102-8. [PMID: 35812024 DOI: 10.1136/flgastro-2022-102122] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
16 Jiang X, Yang Z, Wang S, Deng S. “Big Data” Approaches for Prevention of the Metabolic Syndrome. Front Genet 2022;13:810152. [DOI: 10.3389/fgene.2022.810152] [Reference Citation Analysis]
17 Tavaglione F, Jamialahmadi O, De Vincentis A, Qadri S, Mowlaei ME, Mancina RM, Ciociola E, Carotti S, Perrone G, Bruni V, Gallo IF, Tuccinardi D, Bianco C, Prati D, Manfrini S, Pozzilli P, Picardi A, Caricato M, Yki-Järvinen H, Valenti L, Vespasiani-Gentilucci U, Romeo S. Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol 2022:S1542-3565(22)00385-8. [PMID: 35421583 DOI: 10.1016/j.cgh.2022.03.044] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
18 Seidelin AS, Nordestgaard BG, Tybjærg-Hansen A, Yaghootkar H, Stender S. A rare genetic variant in the manganese transporter SLC30A10 and elevated liver enzymes in the general population. Hepatol Int 2022. [PMID: 35397106 DOI: 10.1007/s12072-022-10331-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Chahal D, Sharma D, Keshavarzi S, Arisar FAQ, Patel K, Xu W, Bhat M. Distinctive clinical and genetic features of lean vs overweight fatty liver disease using the UK Biobank. Hepatol Int 2022. [PMID: 35178663 DOI: 10.1007/s12072-022-10304-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
20 Park S, Lee S, Kim Y, Cho S, Kim K, Chul Kim Y, Han SS, Lee H, Lee JP, Joo KW, Lim CS, Kim YS, Kim DK. Causal effects from non-alcoholic fatty liver disease on kidney function: A Mendelian randomization study. Liver Int 2022;42:412-8. [PMID: 34843158 DOI: 10.1111/liv.15118] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
21 Du X, DeForest N, Majithia AR. Human Genetics to Identify Therapeutic Targets for NAFLD: Challenges and Opportunities. Front Endocrinol (Lausanne) 2021;12:777075. [PMID: 34950105 DOI: 10.3389/fendo.2021.777075] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Haas ME, Pirruccello JP, Friedman SN, Wang M, Emdin CA, Ajmera VH, Simon TG, Homburger JR, Guo X, Budoff M, Corey KE, Zhou AY, Philippakis A, Ellinor PT, Loomba R, Batra P, Khera AV. Machine learning enables new insights into genetic contributions to liver fat accumulation. Cell Genom 2021;1:100066. [PMID: 34957434 DOI: 10.1016/j.xgen.2021.100066] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
23 Ghodsian N, Abner E, Emdin CA, Gobeil É, Taba N, Haas ME, Perrot N, Manikpurage HD, Gagnon É, Bourgault J, St-Amand A, Couture C, Mitchell PL, Bossé Y, Mathieu P, Vohl MC, Tchernof A, Thériault S, Khera AV, Esko T, Arsenault BJ. Electronic health record-based genome-wide meta-analysis provides insights on the genetic architecture of non-alcoholic fatty liver disease. Cell Rep Med 2021;2:100437. [PMID: 34841290 DOI: 10.1016/j.xcrm.2021.100437] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
24 O’dushlaine C, Germino M, Verweij N, Nielsen JB, Yadav A, Benner C, Backman JD, Lin N, R. Abecasis G, Baras A, Ferreira MA, Lotta LA, Walls JR, Parasoglou P, Marchini JL. Genome-wide association study of liver fat, iron, and extracellular fluid fraction in the UK Biobank.. [DOI: 10.1101/2021.10.25.21265127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Im YR, Hunter H, de Gracia Hahn D, Duret A, Cheah Q, Dong J, Fairey M, Hjalmarsson C, Li A, Lim HK, McKeown L, Mitrofan CG, Rao R, Utukuri M, Rowe IA, Mann JP. A Systematic Review of Animal Models of NAFLD Finds High-Fat, High-Fructose Diets Most Closely Resemble Human NAFLD. Hepatology 2021;74:1884-901. [PMID: 33973269 DOI: 10.1002/hep.31897] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 14.0] [Reference Citation Analysis]
26 Wang J, Conti DV, Bogumil D, Sheng X, Noureddin M, Wilkens LR, Le Marchand L, Rosen HR, Haiman CA, Setiawan VW. Association of Genetic Risk Score With NAFLD in An Ethnically Diverse Cohort. Hepatol Commun 2021;5:1689-703. [PMID: 34558842 DOI: 10.1002/hep4.1751] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
27 Fairfield CJ, Drake TM, Pius R, Bretherick AD, Campbell A, Clark DW, Fallowfield JA, Hayward C, Henderson NC, Joshi PK, Mills NL, Porteous DJ, Ramachandran P, Semple RK, Shaw CA, Sudlow CLM, Timmers PRHJ, Wilson JF, Wigmore SJ, Harrison EM, Spiliopoulou A. Genome-Wide Association Study of NAFLD Using Electronic Health Records. Hepatol Commun 2021. [PMID: 34535985 DOI: 10.1002/hep4.1805] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
28 Luo F, Oldoni F, Das A. TM6SF2: A Novel Genetic Player in Nonalcoholic Fatty Liver and Cardiovascular Disease. Hepatol Commun 2021. [PMID: 34532996 DOI: 10.1002/hep4.1822] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Atabaki-pasdar N, Pomares-millan H, Koivula RW, Tura A, Brown A, Viñuela A, Agudelo L, Coral D, van Oort S, Allin K, Chabanova E, Cederberg H, De Masi F, Elders P, Tajes JF, Forgie IM, Hansen TH, Heggie A, Jones A, Kokkola T, Mahajan A, Mcdonald TJ, Mcevoy D, Tsirigos K, Teare H, Vangipurapu J, Vestergaard H, Adamski J, Beulens JW, Brunak S, Dermitzakis E, Hansen T, Hattersley AT, Laakso M, Pedersen O, Ridderstråle M, Ruetten H, Rutters F, Schwenk JM, Walker M, Giordano GN, Ohlsson M, Gupta R, Mari A, Mccarthy MI, Thomas EL, Bell JD, Pavo I, Pearson ER, Franks PW. Inferring causal pathways between metabolic processes and liver fat accumulation: an IMI DIRECT study.. [DOI: 10.1101/2021.08.31.21262709] [Reference Citation Analysis]
30 Lefebvre P, Staels B. Hepatic sexual dimorphism - implications for non-alcoholic fatty liver disease. Nat Rev Endocrinol 2021;17:662-70. [PMID: 34417588 DOI: 10.1038/s41574-021-00538-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
31 Ward LD, Tu HC, Quenneville CB, Tsour S, Flynn-Carroll AO, Parker MM, Deaton AM, Haslett PAJ, Lotta LA, Verweij N, Ferreira MAR, Baras A, Hinkle G, Nioi P; Regeneron Genetics Center., Geisinger-Regeneron DiscovEHR Collaboration. GWAS of serum ALT and AST reveals an association of SLC30A10 Thr95Ile with hypermanganesemia symptoms. Nat Commun 2021;12:4571. [PMID: 34315874 DOI: 10.1038/s41467-021-24563-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
32 Liu Y, Basty N, Whitcher B, Bell JD, Sorokin EP, van Bruggen N, Thomas EL, Cule M. Genetic architecture of 11 organ traits derived from abdominal MRI using deep learning. Elife 2021;10:e65554. [PMID: 34128465 DOI: 10.7554/eLife.65554] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 14.5] [Reference Citation Analysis]
33 Liebe R, Esposito I, Bock HH, Vom Dahl S, Stindt J, Baumann U, Luedde T, Keitel V. Diagnosis and management of secondary causes of steatohepatitis. J Hepatol 2021;74:1455-71. [PMID: 33577920 DOI: 10.1016/j.jhep.2021.01.045] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 12.5] [Reference Citation Analysis]
34 Fairfield CJ, Drake TM, Pius R, Bretherick AD, Campbell A, Clark DW, Fallowfield JA, Hayward C, Henderson NC, Joshi PK, Mills NL, Porteous DJ, Ramachandran P, Semple RK, Shaw CA, Sudlow CL, Timmers PR, Wilson JF, Wigmore SJ, Harrison EM, Spiliopoulou A. Genome-Wide Association Study of Non-Alcoholic Fatty Liver Disease Identifies Association with Apolipoprotein E.. [DOI: 10.1101/2021.05.05.21256592] [Reference Citation Analysis]
35 Roca-Fernández A, Dennis A, Nicholls R, McGonigle J, Kelly M, Banerjee R, Banerjee A, Sanyal AJ. Hepatic Steatosis, Rather Than Underlying Obesity, Increases the Risk of Infection and Hospitalization for COVID-19. Front Med (Lausanne) 2021;8:636637. [PMID: 33855033 DOI: 10.3389/fmed.2021.636637] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
36 Park S, Lee S, Kim Y, Cho S, Kim K, Kim YC, Han SS, Lee H, Lee JP, Joo KW, Lim CS, Kim YS, Kim DK. Causal effects from non-alcoholic fatty liver disease on kidney function: A Mendelian randomization study.. [DOI: 10.1101/2021.02.22.21252263] [Reference Citation Analysis]
37 Pirola CJ, Sookoian S. NAFLD and Cardiometabolic Risk Factors: The Liver Fibrosis Trajectory Through the Lens of Biological Interactions. Hepatology 2021;73:479-82. [PMID: 33280151 DOI: 10.1002/hep.31672] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Teo K, Abeysekera KWM, Adams L, Aigner E, Anstee QM, Banales JM, Banerjee R, Basu P, Berg T, Bhatnagar P, Buch S, Canbay A, Caprio S, Chatterjee A, Ida Chen YD, Chowdhury A, Daly AK, Datz C, de Gracia Hahn D, DiStefano JK, Dong J, Duret A, Emdin C, Fairey M, Gerhard GS, Guo X, Hampe J, Hickman M, Heintz L, Hudert C, Hunter H, Kelly M, Kozlitina J, Krawczyk M, Lammert F, Langenberg C, Lavine J, Li L, Lim HK, Loomba R, Luukkonen PK, Melton PE, Mori TA, Palmer ND, Parisinos CA, Pillai SG, Qayyum F, Reichert MC, Romeo S, Rotter JI, Im YR, Santoro N, Schafmayer C, Speliotes EK, Stender S, Stickel F, Still CD, Strnad P, Taylor KD, Tybjærg-Hansen A, Umano GR, Utukuri M, Valenti L, Wagenknecht LE, Wareham NJ, Watanabe RM, Wattacheril J, Yaghootkar H, Yki-Järvinen H, Young KA, Mann JP; EU-PNAFLD Investigators, GOLD Consortium. rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis. J Hepatol 2021;74:20-30. [PMID: 32882372 DOI: 10.1016/j.jhep.2020.08.027] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 16.5] [Reference Citation Analysis]
39 Ghodsian N, Abner E, Emdin CA, Gobeil É, Taba N, Haas ME, Perrot N, Manikpurage HD, Gagnon É, Bourgault J, St-amand A, Couture C, Mitchell PL, Bossé Y, Mathieu P, Vohl M, Tchernof A, Thériault S, Khera AV, Esko T, Arsenault B. Electronic Health Record-Based Genome-Wide Meta-Analysis Provides New Insights on the Genetic Architecture of Non-Alcoholic Fatty Liver Disease. SSRN Journal. [DOI: 10.2139/ssrn.3865274] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Im YR, Hunter H, de Gracia Hahn D, Duret A, Cheah Q, Dong J, Fairey M, Hjalmarsson C, Li A, Lim HK, Mckeown L, Mitrofan C, Rao R, Utukuri M, Rowe IA, Mann JP. A systematic analysis of rodent models implicates adipogenesis and innate immunity in pathogenesis of fatty liver disease.. [DOI: 10.1101/2020.12.15.422799] [Reference Citation Analysis]
41 Chung GE, Shin E, Kwak MS, In Yang J, Lee JE, Choe EK, Yim JY. The association of genetic polymorphisms with nonalcoholic fatty liver disease in a longitudinal study. BMC Gastroenterol 2020;20:344. [PMID: 33059586 DOI: 10.1186/s12876-020-01469-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
42 Haas ME, Pirruccello JP, Friedman SN, Emdin CA, Ajmera VH, Simon TG, Homburger JR, Guo X, Budoff M, Corey KE, Zhou AY, Philippakis A, Ellinor PT, Loomba R, Batra P, Khera AV. Machine learning enables new insights into clinical significance of and genetic contributions to liver fat accumulation.. [DOI: 10.1101/2020.09.03.20187195] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
43 Mealer RG, Jenkins BG, Chen CY, Daly MJ, Ge T, Lehoux S, Marquardt T, Palmer CD, Park JH, Parsons PJ, Sackstein R, Williams SE, Cummings RD, Scolnick EM, Smoller JW. The schizophrenia risk locus in SLC39A8 alters brain metal transport and plasma glycosylation. Sci Rep 2020;10:13162. [PMID: 32753748 DOI: 10.1038/s41598-020-70108-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 10.0] [Reference Citation Analysis]
44 Perakakis N, Stefanakis K, Mantzoros CS. The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease. Metabolism 2020;111S:154320. [PMID: 32712221 DOI: 10.1016/j.metabol.2020.154320] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 12.3] [Reference Citation Analysis]
45 Liu Y, Basty N, Whitcher B, Bell JD, Sorokin E, van Bruggen N, Thomas EL, Cule M. Genetic architecture of 11 abdominal organ traits derived from abdominal MRI using deep learning.. [DOI: 10.1101/2020.07.14.187070] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
46 Meroni M, Longo M, Fracanzani AL, Dongiovanni P. MBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD. EBioMedicine 2020;57:102866. [PMID: 32629394 DOI: 10.1016/j.ebiom.2020.102866] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
47 Ward LD, Tu H, Quenneville CB, Tsour S, Flynn-carroll AO, Parker MM, Deaton AM, Haslett PAJ, Lotta LA, Verweij N, Ferreira MAR, Baras A, Hinkle G, Nioi P, Regeneron Genetics Center, Geisinger-Regeneron DiscovEHR Collaboration. GWAS of serum ALT and AST reveals an association of SLC30A10 Thr95Ile with hypermanganesemia symptoms.. [DOI: 10.1101/2020.05.19.104570] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
48 Teo K, Abeysekera KWM, Adams L, Aigner E, Banales JM, Banerjee R, Basu P, Berg T, Bhatnagar P, Buch S, Canbay A, Caprio S, Chatterjee A, Chen YI, Chowdhury A, Datz C, de Gracia Hahn D, Distefano JK, Dong J, Duret A, Emdin C, Fairey M, Gerhard GS, Guo X, Hampe J, Hickman M, Heintz L, Hudert C, Hunter H, Kelly M, Kozlitina J, Krawczyk M, Lammert F, Langenberg C, Lavine J, Li L, Lim HK, Loomba R, Luukkonen PK, Melton PE, Mori TA, Palmer ND, Parisinos CA, Pillai SG, Qayyum F, Reichert MC, Romeo S, Rotter JI, Im YR, Santoro N, Schafmayer C, Speliotes EK, Stender S, Stickel F, Still CD, Strnad P, Taylor KD, Tybjærg-hansen A, Umano GR, Utukuri M, Valenti L, Wagenknecht LE, Wareham NJ, Watanabe RM, Wattacheril J, Yaghootkar H, Yki-järvinen H, Young KA, Mann JP, EU-PNAFLD Investigators, GOLD Consortium. rs641738C>T near MBOAT7 is positively associated with liver fat, ALT, and histological severity of NAFLD: a meta-analysis.. [DOI: 10.1101/19013623] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
49 [DOI: 10.1101/2020.06.04.20122457] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Reference Citation Analysis]